Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
At the same time, the company has filed FDA new drug applications for ulixacaltamide and relutrigine, both with Breakthrough Therapy Designation, signaling a possible shift from pure R&D focus toward commercial operations in central nervous system disorders. Now we'll examine how this strengthened cash runway into 2028 could reshape Praxis Precision Medicines' existing investment narrative and risk profile. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it . Find the list for free. Praxis Precision Medicines Investment Narrative Recap To own Praxis Precision Medicines, you have to believe that its late stage CNS pipeline can translate into approved therapies and a sustainable business as it potentially shifts toward commercialization. In the near term, the key catalyst is regulatory progress on the NDAs for ulixacaltamide and relutrigine, while the biggest risk remains clinical or regulator
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines (PRAX) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit [Yahoo! Finance]Yahoo! Finance
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter [Yahoo! Finance]Yahoo! Finance
- Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? [Yahoo! Finance]Yahoo! Finance
- Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue [Yahoo! Finance]Yahoo! Finance
PRAX
Earnings
- 2/19/26 - Miss
PRAX
Sec Filings
- 2/19/26 - Form S-8
- 2/19/26 - Form 10-K
- 2/19/26 - Form 8-K
- PRAX's page on the SEC website